The U.S. remains the largest market for Indian pharmaceutical exports, despite challenges such as falling drug prices and high inventory levels.
India’s pharmaceutical sector has achieved a historic milestone this fiscal year, with exports reaching a record $31.1 billion. This figure underscores India’s reputation as the “pharmacy of the world.” However, a closer examination of the American market reveals significant challenges that Indian manufacturers must navigate.
According to a report by the Economic Times, the United States continues to be the primary destination for Indian pharmaceuticals, accounting for approximately 34% of all outbound shipments. Yet, recent months have indicated a cooling trend in the U.S. market.
Industry experts attribute this slowdown to a substantial inventory buildup within U.S. distribution channels. This situation was largely driven by aggressive purchasing in late 2025, as buyers sought to preemptively stock up in anticipation of changing trade tariffs on patented drugs. As warehouses reached capacity, the demand for new shipments diminished, leading to a notable 10% decline in exports to the U.S. in March.
In addition to logistical challenges posed by full warehouses, Indian manufacturers are facing a “race to the bottom” in terms of pricing for generic drugs. The cost of standard generics in American pharmacies has continued to decline, which is squeezing profit margins for the companies that produce them.
This evolving landscape means that workers in manufacturing hubs like Hyderabad and Ahmedabad must adapt to a new reality. The reliance on high-volume, low-cost “copycat” drugs is being challenged by the volatility of the U.S. market, highlighting the need for a more resilient supply chain that does not depend solely on a single Western partner.
“The U.S. inventory buildup due to tariffs is the primary reason for this slowdown,” said Namit Joshi, chairman of the Pharmaceuticals Export Promotion Council of India (Pharmexcil), in an interview with the Economic Times. He emphasized that while the inventory issues may be temporary as stockpiles are depleted, the structural shift toward lower margins for generics is a permanent reality that necessitates a pivot in business models.
In response to the slowdown in the U.S. market, Indian pharmaceutical firms are actively diversifying their reach. While exports to the North American region faced challenges, with NAFTA region exports declining by 7.9%, India has experienced double-digit growth in emerging markets. Exports to Africa surged by 13%, while shipments to Oceania and Latin America increased by 11.5% and 10%, respectively.
Moreover, there is a concerted effort among Indian companies to move up the value chain into more complex medical fields. Instead of focusing solely on basic tablets, manufacturers are finding success in the production of vaccines, which saw a remarkable growth of 26.4%, reaching $1.5 billion this year.
For American consumers, the continued presence of Indian pharmaceuticals is crucial for maintaining manageable healthcare costs. However, the record export figure of $31.1 billion serves as both a celebration of past achievements and a cautionary note for the future. The sustainability of the industry may depend not on simply producing cheaper products, but on the ability of Indian scientists and manufacturers to innovate and explore new markets beyond traditional Western borders.
As the pharmaceutical landscape evolves, it remains to be seen how Indian manufacturers will adapt to these challenges and opportunities in the coming years.
According to the Economic Times, the future of Indian pharma exports will rely heavily on innovation and diversification.